Member Info for KUMS

As impatient people drop out, once again sp is looking very attractive.

With the oil price and uncertainties in the market, it seems not much is happening in other stocks except oil stocks. That gives good opp to get into stocks one thinks will do will in 6/12 mths time. I am sure the coy is working hard behind the scene and momentum can suddenly change once we get closer to the next news. Good post from EB.

Noted! Time to just hold & wait.

came in very FAST to take advantage of sp.

I read before is very small and mostly heald by EIS investors so this could move up fast on some solid news. Hence why not to buy/top up at this low sp! Makes sense. GLA!

The key to this coy now is Adams Reynolds who brought to us OPTI. The sp there has risen c900% (now c700%). So it's time to top up etc and sit back & relax here.

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "We are world leaders in the development of lentiviral vector-based products and the successful commissioning of our second manufacturing facility is a landmark achievement for Oxford BioMedica. This investment brings significant potential not only to support our own current and future pipeline of gene and cell therapy products in development but also to support our key collaboration with Novartis. Our IP, know-how, manufacturing operations and capacity now position Oxford BioMedica very strongly for securing further new partnerships and alliances." World Leader & capacity now for new P'ships & alliances. Recent appointment of Dr. Lorenzo Tallarigo with USA connections & experience. Looking good!

http://www.oxfordbiomedica.co.uk/press-releases/oxford-biomedica-announces-successful-mhra-inspection-and-approval-to-manufacture-at-its-new-facility-in-yarnton-oxford/ Part of RNS. Oxford, UK - 13 January 2016: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, today announces that it has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture bulk drug material for Investigational Medicinal Products (IMPs) at the Group's recently established and commissioned specialist biomanufacturing facility in Yarnton, Oxford, UK. The successful delivery and licensing of the Yarnton facility provides the Group with a second fully independent GMP manufacturing site, strengthening the robustness of the Group's biologics supply chain, adding dual sourcing capability and doubling capacity. This additional capacity will support Oxford BioMedica's own proprietary programmes in development as well as consolidating key current and potential new strategic relationships such as the well-established CAR-T focussed partnership with Novartis for CTL-019.

Oil shares tumbling and more & more investment will come into Health/Bio/Pharma stocks as more and more people are needing the health service etc. This has just been right for me to get in shares like this early. Just to recap the appointment in December 2015. Appointment of Non-executive Director In line with the Company's strategy to acquire companies or businesses in the healthcare sector, Fastnet (AIM: FAST, ESM: FOI) is pleased to announce the appointment, with immediate effect, of Mr. Harry Stratford as a Non-Executive Director. Harry has over 40 years' experience in the pharmaceutical industry and has built two successful publicly listed pharmaceutical companies. Harry founded Shire Plc in 1986 and was CEO for almost a decade. The Company has grown from humble beginnings to be one of Europe's largest specialty pharmaceutical companies with a market cap of around $40 billion and its stock is a constituent of the FTSE100 index. Harry then went on to be founder, CEO and Executive Chairman of Prostrakan Plc, another International specialty pharmaceutical company, which was subsequently acquired by Kyowa Hakko Kirin of Japan in 2011. Harry holds a BSc. in Chemistry from the University of London and was awarded an OBE in the 2007 New Year's Honours list for his contribution to the Scottish Life Sciences Industry. Cathal Friel, Non-Executive Chairman, commented: "We are delighted to welcome Harry to the Board as a Non-executive Director. We look forward to working with him as we investigate potential acquisition opportunities within the healthcare sector, where we expect his extensive knowledge and experience of the specialty and orphan drug pharmaceutical industry will be of particular value."

now.

now!

back to 2.95 not Bid!

& bid back to 2.95. MMs play a game for weak holders to sell & then they change the spread!

up like we had between 6 & 7 p.

More sellers cleared the better for us to clear 3p and beyond. Buyers are always waiting for the bargain. It will be those buying now who will do the talking then whether to take some profit etc once we pass 3p.

Yes I have done few of those already and it should only get better as we draw nearer to the next news. I am really excited about FAST specially with the recent appointment.

paid.

of news on trials to come out imo, and sp will pick up as we have seen in last few weeks. ASK now 7.95!

Agree. A month ago SP was 2.23p and now knocking on 3p and this is even before we have got going. We will have red days but buyers are out there to pick up the bargain on any weakness in sp. By the way, a month & half ago we were 2.02p! Hoping for a repeat prescription of OPTI here. So nice profit expected whilst getting in inside 3p from what I read from discussion here at the weekend.

buy was after 450k sell, so shares are being picked up and this is good to see.